<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20141028019716N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-08-05</date_registration>
      <primary_sponsor>Bojnourd University of Medical Sciences</primary_sponsor>
      <public_title>The effect of probiotics on enteral milk tolerance and prevention of Necrotizing Enterocolitis in preterm infants hospitalization</public_title>
      <acronym>NEC</acronym>
      <scientific_title>The effect of probiotics on enteral milk tolerance and prevention of Necrotizing Enterocolitis in preterm infants hospitalization</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-07-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64715</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Other design features: In the clinical trial studies, using the tables for the preparation of samples, considering five items, which include: 1- The difference in treatment responses that should be taken 2- The estimation of the amount of treatment responses in one of the groups under research 3- The amount of significant difference Statistics (α), 4- the desired strength of the research (β-1) and 5- whether the experiment is one-sided or two-sided, the sample size in each group is estimated.In this study, the researcher expects a 30% difference in milk tolerance in the two intervention and control groups, and considering the 10% milk tolerance [R1] in the control group and considering the type 1 error (α) of 0.05 and the power of the study (β-1) 80% and taking into account one-sided tests in examining the difference and relationship between groups, the sample size is 30 people in each group and taking into account 30% dropout (n*0.1.1 3), 43 people will be examined in each group, Randomization description: According to the size of the samples, 30 babies will be identified by random block method with 4 blocks and using random numbers table of Random Allocation Software. Blocking and allocation sequence for concealment will be done by a person not involved in the research. The allocation ratio of the samples will be 1:1 and it will be divided into two groups receiving the product of biofermentation company and the control group. This study is double-blind and blinding will take place, Blinding description: Before the start of the study, solution A and B will be provided to the study administrator by Biot Khamtir, who will be the participant, researcher, healthcare personnel (doctors, nurses), clinical supervisor, and outcome evaluator until the end of the study. Except for the manufacturer of the solution, they are blind and do not know which of the mentioned solutions is drug or non-drug.</study_design>
      <phase>3</phase>
      <hc_freetext>and prevention of Necrotizing Enterocolitis in preterm.</hc_freetext>
      <i_freetext>Intervention 1: intervention group: After the baby's feeding volume reaches 5 cc/kg/d, oral probiotics from Bio Fermentation Company at the rate of one drop per kilogram of body weight with normal saline solution up to a volume of 5. cc diluted, administered every 12 hours. Intervention 2: In the control group: Only equivalent to 5/. CC of normal saline solution was administered every 12 hours.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Need for more studies</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Ghasem Bayani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>North Khorasan  ,bojnord,bernji allley</address>
        <city>Bojnord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>2247124</zip>
        <telephone>+98 58 4221 1008</telephone>
        <email>bayani.ghasem@yahoo.com</email>
        <affiliation>Bojnourd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Ghasem Bayani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>North Khorasan  ,bojnord,bernji allley</address>
        <city>Bojnord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>2247124</zip>
        <telephone>+98 58 4221 1008</telephone>
        <email>bayani.ghasem@yahoo.com</email>
        <affiliation>Bojnourd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Entry condition for pregnancy age below 30 weeks
and birth weight less than 1500 grams</inclusion_criteria>
      <agemin>168 months</agemin>
      <agemax>210 days</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Babies with gastrointestinal obstruction, congenital heart disease, amphalocele, gastroschisis, grade 2 and 3 asphyxiaCommunity Verified icon
Babies of addicted mothers(Because one of the problems of babies born to addicted mothers is digestive problems such as feeding intolerance and abdominal distention and diarrhea, which can overlap with the symptoms of necrotizing enterocolitis).Community Verified icon
Failure to receive enteral nutrition in the first 48 hours of birth
Death of a premature baby
Congenital and chromosomal malformations in the digestive system of premature babies
Active gastrointestinal bleeding in the first week after birth</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P77.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Necrotizing enterocolitis in newborn, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>intervention group: After the baby's feeding volume reaches 5 cc/kg/d, oral probiotics from Bio Fermentation Company at the rate of one drop per kilogram of body weight with normal saline solution up to a volume of 5. cc diluted, administered every 12 hours</i_keyword>
      <i_keyword>In the control group: Only equivalent to 5/. CC of normal saline solution was administered every 12 hours.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Prevention of necrotizing enterocolitis. Timepoint: When a premature baby is hospitalized. Method of measurement: Definitive diagnosis of necrotizing enterocolitis by a neonatologist.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>1. Duration of hospitalization. Timepoint: Weight of premature baby at admission and at discharge. Method of measurement: The weight of the premature baby is in grams at the time of hospitalization And the time is based on hours and minutes and Increase in head circumference based on centimeters.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Bojnourd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-26</approval_date>
        <contact_name>Research Ethics Committee of North Khorasan University of Medical Sciences</contact_name>
        <contact_address>honar Street,Bent Al Hadi Hospital bojnurd North Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
